U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C24H31NO.ClH
Molecular Weight 385.97
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIPIPANONE HYDROCHLORIDE

SMILES

Cl.CCC(=O)C(CC(C)N1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=DTXPDSQEMZRBBG-UHFFFAOYSA-N
InChI=1S/C24H31NO.ClH/c1-3-23(26)24(21-13-7-4-8-14-21,22-15-9-5-10-16-22)19-20(2)25-17-11-6-12-18-25;/h4-5,7-10,13-16,20H,3,6,11-12,17-19H2,1-2H3;1H

HIDE SMILES / InChI
Molecular Formula C24H31NO
Molecular Weight 349.509
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.druginfosys.com/drug.aspx?drugcode=252&type=1 | doi: 10.1007/978-3-540-68706-1_1823 | Miller, R.L. (2002) "The Encyclopedia of Addictive Drugs", p.130 Retrieved from https://books.google.ru/books?id=G7As-qawdzMC

Dipipanone are indicated for the management of moderate to severe pain in medical and surgical conditions in which morphine may be indicated. Dipipanone is related to methadone and can be substituted for assorted opioids. The severe or irreversible adverse effects of Dipipanone, which give rise to further complications, include hypotension, hypotension, hependence, agranulocytosis, ischemic colitis, generalized chorea, hypersensitivity hepatitis. It may interact badly with monoamine oxidase inhibitors, which are substances found in some antidepressants and other medication.

Originator

Ofner, P.|Walton, E.
4
Sources: DOI: 10.1039/JR9500002158

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Not Provided
511
Diconal

Approved Use

Dipipanone has no officially approved medical usage in the United States, but elsewhere it is used as a powerful pain reliever.
PubMed

PubMed

TitleDatePubMed
Psychotic symptoms after dipipanone.
1978 Aug 26
Prescription of diamorphine, dipipanone and cocaine in England and Wales.
1997 Sep
Patents

Patents

GB654975
4
JP2005520783A
40

Sample Use Guides

In Vivo Use Guide
The initial dose in all conditions is Dipipanone 10 mg (+ 30 mg Cyclizine) every 6 hours. It is seldom necessary to exceed a dose of 30 mg dipipanone given 6-hourly.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:48:53 GMT 2025
Edited
by admin
on Mon Mar 31 17:48:53 GMT 2025
Record UNII
8VY00AJ0RL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIPIPANONE HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
FENPIDON
Preferred Name English
HOECHST-10805
Code English
DIPIPANONE HCL
Common Name English
DIPIPANONE HYDROCHLORIDE [MI]
Common Name English
3-HEPTANONE, 4,4-DIPHENYL-6-(1-PIPERIDINYL)-, HYDROCHLORIDE
Systematic Name English
DIPIPANONE HYDROCHLORIDE [MART.]
Common Name English
PIPADONE
Brand Name English
378C48
Code English
Dipipanone hydrochloride [WHO-DD]
Common Name English
4,4-DIPHENYL-6-PIPERIDINO-3-HEPTANONE HYDROCHLORIDE
Systematic Name English
(±)-DIPIPANONE HYDROCHLORIDE
Common Name English
HOECHST 10805
Code English
DIPIPANONE HYDROCHLORIDE, (±)-
Common Name English
3-HEPTANONE, 4,4-DIPHENYL-6-(1-PIPERIDINYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
Code System Code Type Description
ECHA (EC/EINECS)
278-307-6
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY
NCI_THESAURUS
C76839
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY
EVMPD
SUB01788MIG
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY
SMS_ID
100000087519
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY
MESH
C007527
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY
MERCK INDEX
m4647
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY Merck Index
FDA UNII
8VY00AJ0RL
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY
ChEMBL
CHEMBL2111157
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY
CAS
75783-06-1
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY
PUBCHEM
13330
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY
EPA CompTox
DTXSID50997178
Created by admin on Mon Mar 31 17:48:53 GMT 2025 , Edited by admin on Mon Mar 31 17:48:53 GMT 2025
PRIMARY
Related Record Type Details
Structure of DIPIPANONE HYDROCHLORIDE, (R)-
ENANTIOMER -> RACEMATE
Structure of DIPIPANONE
PARENT -> SALT/SOLVATE
Structure of DIPIPANONE HYDROCHLORIDE, (S)-
ENANTIOMER -> RACEMATE
Structure of DIPIPANONE HYDROCHLORIDE MONOHYDRATE
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of DIPIPANONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966